We prioritized 57 druggable targets from 212 putative causal genes of metabolic-dysfunction-associated steatotic liver disease (MASLD). Using a drug-repurposing analysis that integrated protein struct...

Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinar...